Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q6RI45

UPID:
BRWD3_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q6RI45; C9IZ39; C9J3F3; Q2T9J6; Q5JRN1; Q6RI37; Q6RI42; Q6RI44; Q8N916

BACKGROUND:
The protein Bromodomain and WD repeat-containing protein 3 plays a crucial role in cell morphology and cytoskeletal organization, necessary for proper cell shape control. Its functions are integral to cellular architecture and dynamics.

THERAPEUTIC SIGNIFICANCE:
Associated with Intellectual developmental disorder, X-linked 93, which manifests as significantly below average intellectual functioning and macrocephaly, the study of Bromodomain and WD repeat-containing protein 3 offers a promising avenue for developing targeted therapies for this condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.